Literature DB >> 15989960

Regulation of apoptosis by alternative pre-mRNA splicing.

Christian Schwerk1, Klaus Schulze-Osthoff.   

Abstract

Apoptosis, a phenomenon that allows the regulated destruction and disposal of damaged or unwanted cells, is common to many cellular processes in multicellular organisms. In humans more than 200 proteins are involved in apoptosis, many of which are dysregulated or defective in human diseases including cancer. A large number of apoptotic factors are regulated via alternative splicing, a process that allows for the production of discrete protein isoforms with often distinct functions from a common mRNA precursor. The abundance of apoptosis genes that are alternatively spliced and the often antagonistic roles of the generated protein isoforms strongly imply that alternative splicing is a crucial mechanism for regulating life and death decisions. Importantly, modulation of isoform production of cell death proteins via pharmaceutical manipulation of alternative splicing may open up new therapeutic avenues for the treatment of disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15989960     DOI: 10.1016/j.molcel.2005.05.026

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  165 in total

1.  Modulation of RNA splicing as a potential treatment for cancer.

Authors:  John A Bauman; Ryszard Kole
Journal:  Bioeng Bugs       Date:  2011-05-01

2.  KHDC1A, a novel translational repressor, induces endoplasmic reticulum-dependent apoptosis.

Authors:  Congli Cai; Jing Liu; Chao Wang; Jinhua Shen
Journal:  DNA Cell Biol       Date:  2012-06-25       Impact factor: 3.311

3.  Human SAP18 mediates assembly of a splicing regulatory multiprotein complex via its ubiquitin-like fold.

Authors:  Kusum K Singh; Steffen Erkelenz; Stephanie Rattay; Anna Katharina Dehof; Andreas Hildebrandt; Klaus Schulze-Osthoff; Heiner Schaal; Christian Schwerk
Journal:  RNA       Date:  2010-10-21       Impact factor: 4.942

4.  The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x.

Authors:  Lulzim Shkreta; Laetitia Michelle; Johanne Toutant; Michel L Tremblay; Benoit Chabot
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

Review 5.  MECHANISMS IN ENDOCRINOLOGY: Alternative splicing: the new frontier in diabetes research.

Authors:  Jonàs Juan-Mateu; Olatz Villate; Décio L Eizirik
Journal:  Eur J Endocrinol       Date:  2015-12-01       Impact factor: 6.664

6.  Developmental Attenuation of Neuronal Apoptosis by Neural-Specific Splicing of Bak1 Microexon.

Authors:  Lin Lin; Min Zhang; Peter Stoilov; Liang Chen; Sika Zheng
Journal:  Neuron       Date:  2020-07-24       Impact factor: 17.173

Review 7.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

8.  Group VIA Phospholipase A2 (iPLA2β) Modulates Bcl-x 5'-Splice Site Selection and Suppresses Anti-apoptotic Bcl-x(L) in β-Cells.

Authors:  Suzanne E Barbour; Phuong T Nguyen; Margaret Park; Bhargavi Emani; Xiaoyong Lei; Mamatha Kambalapalli; Jacqueline C Shultz; Dayanjan Wijesinghe; Charles E Chalfant; Sasanka Ramanadham
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

9.  RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML.

Authors:  Leslie A Crews; Larisa Balaian; Nathaniel P Delos Santos; Heather S Leu; Angela C Court; Elisa Lazzari; Anil Sadarangani; Maria A Zipeto; James J La Clair; Reymundo Villa; Anna Kulidjian; Rainer Storb; Sheldon R Morris; Edward D Ball; Michael D Burkart; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2016-08-25       Impact factor: 24.633

10.  Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5' splice site selection.

Authors:  Anyu Zhou; Alexander C Ou; Aeri Cho; Edward J Benz; Shu-Ching Huang
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.